

## NEWSLETTER

### CHEMICAL & PHARMACEUTICAL

5 - 11 January 2026



#### **India withdraws anti-dumping duties on Chinese titanium dioxide**

The Central Board of Indirect Taxes and Customs (CBIC) of India issued Customs Directive 33/2025, instructing all local agencies to cease imposing anti-dumping duties on imports of titanium dioxide (titanium dioxide) originating from or exported from China. This decision will significantly alleviate export pressure on Chinese titanium dioxide. **(ChemNet Chemical Headlines)**

#### **Sinopec and LG Chem to jointly develop key materials for sodium-ion batteries**

China Petroleum and Chemical Corp (Sinopec) signed a strategic agreement with South Korean petrochemical giant LG Chem to jointly develop key materials for sodium-ion batteries. The collaboration will see the two industrial heavyweights co-develop cathode and anode materials for the burgeoning sodium-ion sector. **(China Daily)**

#### **Sichuan Province's only aluminum-based new materials industry development base**

Guangyuan City, located in northern Sichuan Province, prioritizes the aluminum-based new materials industry as its leading sector. The city has an electrolytic aluminum production capacity of 615,000 tons, accounting for 58% of Sichuan Province's total capacity, a recycled aluminum production capacity of 1.6 million tons, and an aluminum processing capacity of 2.2 million tons. It has attracted over 100 high-quality aluminum enterprises. **(China News Network)**

#### **AstraZeneca exec bullish on China's pharma industry**

An AstraZeneca executive has expressed strong confidence in China's pharmaceutical industry, citing clear government support for innovative drug development. The company plans to introduce nearly 10 new rare disease products or indications to the Chinese market in the next five years. China's growing medical insurance spending on innovative drugs, which surged 40% annually, reinforces this positive outlook. **(China Daily)**

#### **Sinovac Biotech announces initiative to boost China's biopharmaceutical supply chain**

Chinese vaccine company Sinovac Biotech has launched the "Laifu Initiative" with 69 partners to strengthen the innovation and resilience of China's biopharmaceutical supply chain. This collaboration marks a shift from traditional buyer-supplier relationships to integrated, full-chain cooperation covering R&D, production, and global expansion. **(China Daily)**